Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;11:8589–8602. doi: 10.2147/CMAR.S186002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) The BGC-823 cells were treated with 5-azacytidine, and the expression level of KCNK15-AS1 increased in a dose-dependent manner, and the expression of HDAC1 and DNMT1 decreased in a dose-dependent manner (^⎂^△^∇P<0.05; ^▁^⋆^△P<0.05; ^△^⎂ ^⋆P<0.05; ^▁^△^⋆P<0.05). (B) The SCG7901 cells was treated with 5-azacytidine. The expression level of KCNK15-AS1 increased in a dose-dependent manner, and the expression of HDAC1 and DNMT1 decreased in a dose-dependent manner (^⎂^▁^∇P<0.05; ^⋆^♦^△P<0.05; ^△^∇^⎂P<0.05; ^▁ ^△ ^⋆P<0.05). (C) The BGC-823 cells were treated with chidamide. The expression level of KCNK15-AS1 increased in a dose-dependent manner, and the expression of HDAC1 and DNMT1 decreased in a dose-dependent manner (^♦^△^∇^△P<0.05; ^⢶^⎂^∇^△P<0.05; ^△ ^⢶^▁^△P<0.05; ^⢶^⋆^♦^△P<0.05). (D) The SCG7901 cells were treated with chidamide. The expression level of KCNK15-AS1 increased in a dose-dependent manner, and the expression of HDAC1 and DNMT1 decreased in a dose-dependent manner (^△^∇^⋆P<0.05; ^▁^⋆^△P<0.05; ^∇^▁^△P<0.05; ^▁^△^⋆P<0.05). (E) Western blot showed the expression levels of HDAC1 and DNMT1 in BGC-823 cells treated with chidamide and 5-azacytidine. (F) Western blot showed the expression levels of HDAC1 and DNMT1 in SCG7901 cells treated with chidamide and 5-azacytidine. (G) After treatment with chidamide and 5-azacytidine, KCNK15-AS1 was unmethylated in both the BGC-823 and SCG7901 cells. (H) The expression of KCNK15-AS1 was decreased after the knockdown of HDAC1 (^⎂P<0.05).